View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 29, 2022

IN8bio reveal early cell therapy data from Phase I leukaemia trial

The safety and toxicity profile of INB-100 continues to be manageable without any Grade 3 or greater adverse events reported.

IN8bio has reported data from the ongoing Phase I clinical trial of its allogeneic gamma-delta T cell therapy candidate, INB-100, to treat leukaemia patients who are undergoing haploidentical hematopoietic stem cell transplant (HSCT). 

So far, three high-risk acute myeloid leukaemia (AML) patients with complex cytogenetics have received the allogeneic derived, gamma-delta T cells that were extended and activated ex vivo. 

The company noted that two of the subjects who received INB-100 have been in remission for 23.3 and 21 months and the third subject is continuing remission at 9.3 months following the cell therapy.

According to the exploratory clinical correlative findings, strong reconstitution of the immune system was observed in patients who received the treatment. 

Positive trends in immune cell levels, including alpha-beta T cells, B cells and gamma-delta T cells were reported. This indicates that in subjects who received the cell therapy, the systemic immune system may demonstrate durable positive trends. 

The safety and toxicity profile of INB-100 continues to be manageable without any therapy-associated Grade 3 or greater adverse events noted. 

The single-institution, dose-escalation trial is underway at The University of Kansas Cancer Center (KUCC) in the US. 

In the trial, INB-100 was given systemically to leukaemia patients after haploidentical HSCT. 

Safety and tolerability are the primary endpoints of the trial while rates of graft versus host disease, overall survival and relapse rate are included as the secondary endpoints.

IN8bio chief scientific officer and co-founder Lawrence Lamb said: “We are encouraged by the patients’ responses to INB-100 treatment given this population’s high risk for recurrence. 

“As we near the two-year mark in remission for our first and longest enrolled patient, we continue to monitor data from our ongoing clinical correlative studies, which are indicating a positive systemic immune response following the infusion of INB-100.”

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena